He Xiaojing, Ma Qingya, Zhang Qiaoli, Hong Xutao, Qi Ming, Li Yongkai, Li Xiaodong
Department of Obstetrics and Gynaecology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Gynecology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Front Genet. 2022 Nov 25;13:1038997. doi: 10.3389/fgene.2022.1038997. eCollection 2022.
Androgen insensitivity syndrome (AIS) is an X-linked recessive hereditary disease caused due to a reduced or absent function of the androgen receptor (AR) protein encoded by the AR gene (OMIM-Gene# 313,700). Genetic testing is important in the diagnosis, clinical management, and prevention of AIS (MIM# 300,068). The AR (HGNC: 644) pathogenic variant detection rate ranges from 65% to 95% for patients with complete AIS (CAIS) and 40%-45% for patients with partial androgen insensitivity syndrome (PAIS). Identification of a pathogenic mutation in the AR confirms the diagnosis of AIS, especially in the milder forms that may have a phenotypic overlap with other disorders of sex development. Improvement of the molecular diagnostic rate of AIS is urgently required in clinical practice. We reported the results of the molecular diagnosis of a patient with CAIS who failed previously in either the traditional Sanger sequencing or next-generation sequencing (NGS). Using whole-exome sequencing (WES) combined with a special polymerase chain reaction (PCR) and deep sequencing, we successfully identified a pathogenic variant, a hemizygous mutation (c.1395-1396insGA), in the GC-enriched and unstable GCC repeat regions of the AR gene of the proband. The results may be advantageous for the improvement of the detection rate of AIS, as well as other inherited disorders whose disease-causing genes contain GC-enriched and unstable GCC repeat regions.
雄激素不敏感综合征(AIS)是一种X连锁隐性遗传病,由AR基因(OMIM基因编号:313,700)编码的雄激素受体(AR)蛋白功能降低或缺失所致。基因检测在AIS(MIM编号:300,068)的诊断、临床管理和预防中具有重要意义。对于完全性雄激素不敏感综合征(CAIS)患者,AR(HGNC:644)致病变异的检测率为65%至95%,对于部分性雄激素不敏感综合征(PAIS)患者,该检测率为40%至45%。AR致病突变的鉴定可确诊AIS,尤其是在可能与其他性发育障碍存在表型重叠的较轻形式中。临床实践中迫切需要提高AIS的分子诊断率。我们报告了一名CAIS患者的分子诊断结果,该患者之前的传统桑格测序或二代测序(NGS)均失败。通过全外显子组测序(WES)结合特殊聚合酶链反应(PCR)和深度测序,我们成功在先证者AR基因富含GC且不稳定的GCC重复区域中鉴定出一个致病变异,即半合子突变(c.1395 - 1396insGA)。这些结果可能有利于提高AIS以及其他致病基因包含富含GC且不稳定GCC重复区域的遗传性疾病的检测率。